BioCentury
ARTICLE | Financial News

BiomX raises $32M series B to bring first two therapies to clinic

February 22, 2019 5:18 PM UTC

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Feb. 20 that will take its lead candidate, acne therapy BX001, into the clinic within the next few months. The company said the round will also provide resources to start clinical testing of its inflammatory bowel disease (IBD) program BX002 toward the end of 2020.

CEO Jonathan Solomon told BioCentury that BiomX has also identified a new liver target to treat primary sclerosing cholangitis (PSC) as well as a cancer target, which was a major driver of the round. Solomon didn't disclose details on the targets, but said the cancer therapy would involve engineered phages, unlike BiomX's IBD and acne programs, which use natural phages...

BCIQ Company Profiles

BiomX Inc.